RU2339389C2 - Method for prevention of nasopharingal of pathogenic microflora carriage - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to epidemiology, and concerns prophylaxes of nasopharingal carriage of a pathogenic microflora. For this purpose daily administer a Vitaflor probiotic intranasaly in a dose 2×10⁸ CFU of lactic acid bacillus into 1 ml of dissolvent. Duration of administration - 3 weeks.

EFFECT: decrease of probability of respiratory diseases at expense of elimination of pathogenic originators and simultaneous stimulation of growth of own useful microflora.

2 tbl

Description

The invention relates to medicine, in particular to epidemiology, in particular to the prevention of nasopharyngeal carriage of pathogenic and conditionally pathogenic bacteria, viruses, mycoplasmas, fungi that cause local or systemic infectious diseases, which can be used for the rehabilitation of nasopharyngeal carriage and, accordingly, for the prevention of acute or chronic respiratory infections.

A known method of reorganization of patients from pathogenic nasopharyngial microflora by using inhalation of antibacterial drugs.

The disadvantage of this method is the low efficiency associated with the possibility of suppressing the vital activity of saprophytes and the development of dysbiosis.

The purpose of the invention is to increase the efficiency of rehabilitation of patients from pathogenic nasopharyngial microflora.

The goal is achieved by the fact that within 3 weeks receive daily three times intranasally 2 · 10 ⁸ colony forming units of lactobacilli probiotic Vitaflor in 1 ml of solvent

The method is implemented as follows.

Taking into account the established antagonistic properties of the strain formula of lactobacilli, the newest generation of probiotic Vitaflor (see table 1) immediately after arrival in the team, all newly examined for the next 3 weeks receive daily three times intranasally 2 drops (0.05 ml) in each nasal passage from dilution with two milliliters of sterile saline solution of two standard calculated doses of Vitaflor probiotic in a standard penicillin vial, which is 2 · 10 ⁸ CFU / ml (colony forming units of lactobacilli in 1 ml of solvent) for 3 weeks under the supervision of comprehensive studies of samples of microbiocenoses of the nasal and pharyngeal broths (see table 2).

The effectiveness of the proposed method is comparable with the well-known sanitation of the nasopharynx with antibiotics or antiseptics, but it has clear advantages in that:

firstly, the proposed method of using probiotic eliminates only pathogenic pathogens and at the same time stimulates the growth of its own beneficial microflora (see table 2), and the use of antibiotics or antiseptics locally eliminates all microflora sensitive to it (including useful) with the possibility of uncontrolled subsequent colonization unwanted bacteria in contact with unsanctioned or incompletely sanitized persons,

secondly, the localized local effect of probiotic or antibiotic preparations on the nasopharyngeal mucosa through the MALT system initiates similar changes on the surfaces of other mucous systems - GALT, TALT, BALT, NALT and others, in which the advantages of the proposed method are quite obvious,

thirdly, the mechanism of elimination of pathogens from the nasopharynx using the Vitaflora probiotic is based on the total, selective and multi-level pathogenetic effects of 9 known lactocins and more than 200 metabolite antigens with different mechanisms of local and systemic action, but again with selective cidal direct or indirect effects on pathogens of bacterial, viral and fungal etiology, in combination with directed and controlled stimulation of the growth of beneficial bacteria, activation of local and systemic x links of immunity, which leads to a more complete sanitation of the nasopharynx and prevents the development of infectious diseases,

fourthly, the claimed method of rehabilitation is more prolonged effective in the duration of the rehabilitation time and does not initiate concomitant antibiotics and antiseptics of allergic reactions,

fifthly, the use of the probiotic Vitaflor according to the claimed method at the cellular and organism levels non-specifically inhibits the formation and manifestations of the formed allergic reactions of types I, III, IV and forms a prophylactic increase in resistance to the development of allergic reactions or sensitization due to a non-specific decrease in the sensitivity of smooth muscles to histamine, serotonin, MDAA and other mediators of allergy, increasing the resistance of cell walls to trigger liberators of active substances-mediators allergies, suppressing the formation of circulating IgG immune complexes, and suppressing the production of pro-inflammatory cytokines [such as interleukin 1 (IL-1), interleukin 2 (IL-2), tumor necrosis factor (TNF-alpha)], suppresses the activity and induction of specific IgE and etc.,

sixthly, in general, the claimed method of sanitation with a probiotic is safer and more effective than antibiotics, antiseptics, antiviral or antifungal drugs alone or when they are complexly prescribed due to local and systemic direct and indirect effects,

seventh, the advantages of the proposed method using Vitaflora over the possible similar use of other known probiotic preparations, for example, the analogue of bifidumbacterin and the prototype lactobacterin, obviously from the data presented in table 1.

Table 1. The spectrum and level of antagonistic activity of Vitaflor monostrains and known production strains of bifidumbacterin (analog) and lactobacterin (prototype). Test culture Zones of growth inhibition of test cultures, mm L. acidophilus D-75 L. acidophilus D-76 L. plantarum 8P-AZ B. bifidum No. 1 L. bucneri No. 96 Gram-positive bacteria Staphylococcus aureus > 45 50> fifty 10 thirty Staphylococcus aureus 236 thirty > 50 > 50 8 25 Staphylococcus xylosus 552 > 30 > 50 thirty 10 40 Staphylococcus xylosus 512 35 > 50 > 50 12 > 50 Staphylococcus warneri 514 > 50 > 30 > 50 10 > 50 Staphylococcus saprophiticus 523 40 > 50 fifty eleven fifty Staphylococcus lentus 542 > 50 > 50 > 50 fourteen > 50 Staphylococcus epidermidis
595 > 50 > 50 > 50 10 > 50 Staphylococcus epidermidis
529 45 > 50 > 50 fifteen > 50 Streptococcus salivarius 518 45 > 50 thirty 10 > 25 Peptococcus sp. 370 40 25 thirty 10 > 50 Micrococcus kristinae 568 > 25 > 50 > 50 10 > 50 Micrococcus kristinae 500 > 30 > 50 > 50 12 > 50 Criptococcus sp.505 10 8 0 0 5 Corinebacterium sp.503 25 35 thirty 10 0 Corinebacterium sp. 543 > 30 > 35 > 50 10 > 50 Gram-negative bacteria Helicobacter pylori 23/5 > 50 > 50 10 0 > 50 Pseudomonas vesiculans 45 > 50 > 50 > 50 10 > 50 Pseudomonas acidovorans 521 > 50 > 50 > 50 10 > 50 Pseudomonas maltophilia 524 > 50 > 50 > 50 0 > 50 Pseudomonas maltophilia 527 > 50 > 50 > 50 0 > 50 Pseudomonas putrefaciens > 50 > 50 > 50 0 > 50 Pseudomonas putrefaciens > 50 > 50 > 50 0 > 50 Pseudomonas cepacia 521 > '50 > 50 > 50 0 > 50 Pseudomonas cepacia 528 > 50 > 50 > 50 2 > 50 Pseudomonas cepacia 548 > 50 > 50 > 50 3 > 50 Pseudomonas fluorescens 554 > 50 > 50 > 50 2 > 50 Enterobacter agglomerans 525 > 50 > 50 > 50 thirty > 50 Alcaligenes denitrificans 415 > 50 > 50 > 50 twenty > 50 Alcaligenes denitrificans 130 > 50 > 50 > 50 25 > 50 Citrobacter freundii 135 > 50 > 50 36 40 40 Serratia marcescens 37 26 > 50 > 50 45 twenty Acinetobacter anitratus 196 > 50 > 50 > 50 twenty > 50 Yeast p.Candic a Candida albicans 531 fifteen fifteen 10 0 10 Candida albicans 386 10 12 12 0 10 Candida albicans 507 0 0 0 0 12 Candida krusei 168 0 0 0 0 10 Candida tropicalis 233 0 0 0 0 10 Candida pseudotropicalis 345 eighteen 24 22 0 10

From the results of comparative studies of antagonistic activity, presented in table 1, the advantages of the strain formula of lactobacilli Vitaflora in comparison with other industrial strains of bifidobacteria and lactobacilli in general and on gram-negative pathogenic microflora, and on gram-positive pathogens, as well as on fungi and yeast are obvious.

table 2 The influence of Vitaflora on reducing the proportion of carriage of pathogens of bacterial and viral nature Type of pathogen Nasopharyngeal carriage by groups (%) Benefits of rehabilitation (krat) Group 3 without Vitaflora Group number 1 Group No. 2 No. 3 / No. 1 No. 3 / No. 2 S. pneumoniae 30,0 16.6 16,4 1.81 1.83 H.influenzae 26.6 3,1 2,5 8.58 10.64 S.aureus 19.3 9.0 10.5 2.14 1.84 M. pneumoniae 8.3 6.4 5.5 1.3 1,5 C. pneumoniae 1.9 1,6 1.4 1,2 1.4 ARVI viruses 2.1 1,6 1.3 1.3 1,6

Thus, it is obvious that using the developed form and strain formula of the Vitaflor probiotic according to the used doses and courses of application in accordance with the claimed method, it is possible to carry out completely safe, absolutely harmless and quite effective nasopharyngeal debridement, based on phylogenetically developed mechanisms of activation of individual links of human immunity, combined with the antagonistic activity of lactobacilli with nasopharyngeal pathogens of bacterial, viral, fungal and chlamydial nature, and at the same time, stimulation by the well-known metabolic pool of lactobacilli of the development of normoflora on the mucous membranes.

Claims (1)

A method for the prevention of nasopharyngeal carriage of pathogenic microflora through the use of therapeutic agents, characterized in that for 3 weeks it is prescribed three times intranasally for 2 · 10 ⁸ colony forming units of the lactobacillus probiotic Vitaflor in 1 ml of solvent.